scholarly article | Q13442814 |
P50 | author | John M. Murray | Q41046114 |
Viviana Simon | Q54435264 | ||
Alan S. Perelson | Q55719625 | ||
Jeroen Vanderhoeven | Q57015306 | ||
P2093 | author name string | Bharat Ramratnam | |
Arlene Hurley | |||
Martin Markowitz | |||
Tian He | |||
David D Ho | |||
Linqi Zhang | |||
Xia Jin | |||
Michael Louie | |||
Chris Chung | |||
Murugappan Ramanathan | |||
Geoffrey R Deschenes | |||
Shady Barsoum | |||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 634-643 | |
P577 | publication date | 2002-08-09 | |
P1433 | published in | Journal of Infectious Diseases | Q4051141 |
P1476 | title | Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination | |
P478 | volume | 186 |
Q27319650 | A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation |
Q34047774 | AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein |
Q35729054 | Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. |
Q36099376 | Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection |
Q40519226 | Advances in the diagnosis and treatment of acute human immunodeficiency virus type 1 (HIV-1) infection |
Q36223710 | Advances in understanding immunologic control of HIV infection |
Q51971392 | An IL-15 dependent CD8 T cell response to selected HIV epitopes is related to viral control in early-treated HIV-infected subjects. |
Q35784804 | Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load |
Q36198648 | Clinical experience with therapeutic AIDS vaccines |
Q34550802 | Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virus-specific CTL. |
Q28472597 | Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood |
Q28554534 | DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus |
Q36474240 | Diminished Proliferation of Human Immunodeficiency Virus-Specific CD4+T Cells Is Associated with Diminished Interleukin-2 (IL-2) Production and Is Recovered by Exogenous IL-2 |
Q28742727 | Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption |
Q26777442 | Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions |
Q33941340 | Features of responding T cells in cancer and chronic infection. |
Q34567084 | Finding a cure for HIV: will it ever be achievable? |
Q38101294 | From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication |
Q40478109 | HIV sequence diversity during the early phase of infection is associated with HIV DNA reductions during antiretroviral therapy. |
Q43130032 | HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. |
Q33731771 | HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound |
Q33745356 | Immune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruption |
Q34351326 | Immune interventions in HIV infection |
Q28183667 | Immunopathogenesis and immunotherapy in AIDS virus infections |
Q34779237 | Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort |
Q24804986 | Limited durability of viral control following treated acute HIV infection |
Q35635412 | Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization |
Q37365718 | Modeling HIV persistence, the latent reservoir, and viral blips |
Q38692205 | New challenges in therapeutic vaccines against HIV infection. |
Q34220902 | No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial |
Q38915896 | Novel immunological strategies for HIV-1 eradication |
Q24799820 | Optimal clinical trial designs for immune-based therapies in persistent viral infections |
Q75300535 | Primary HIV Infection |
Q81433335 | Primary HIV-1 Infection: Diagnosis, Pathogenesis, and Treatment |
Q36223861 | Primary human immunodeficiency virus type 1 infection |
Q73733752 | Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251 |
Q33698152 | Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit |
Q33332291 | Resisting immune exhaustion in HIV-1 infection. |
Q46856608 | Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection |
Q35108735 | Supervised interruptions of antiretroviral therapy |
Q33586581 | The detection and management of early HIV infection: a clinical and public health emergency |
Q36223826 | Therapeutic HIV vaccines: an update |
Q36238709 | Therapeutic immunization strategies for the control of HIV-1. |
Q36846254 | Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire |
Q94923880 | Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques |
Q38013505 | Therapeutic vaccines against HIV infection |
Q35140817 | Therapeutic vaccines against HIV need international partnerships |
Q38626469 | Toward a cure for HIV--Seeking effective therapeutic vaccine strategies |
Q36280900 | Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort |
Q38209874 | Update on antiretroviral treatment during primary HIV infection |
Q34409178 | Vaccines: past, present and future |
Search more.